logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Organicell Regenerative Medicine, Inc. Secures Additional $11 Million In Financing In Preparation For Clinical Trial Enrollment

Sep 09, 2022•over 3 years ago

Amount Raised

$11 Million

Miami

Description

MIAMI, FL / September 9, 2022 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological therapeutics and regenerative medicine, has closed on an additional $1 million private stock purchase at $0.04 per share and secured a $10 Million Equity Line of Credit with Tysadco Partners, LLC.

Company Information

Company

Organicell Regenerative Medicines

Location

Miami, Florida, United States

About

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/.

Related People

3 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech